永安药业(002365) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 412,209,105.79, representing a 31.57% increase compared to CNY 313,310,488.45 in the same period last year[4] - Net profit attributable to shareholders reached CNY 50,589,943.61, a significant increase of 544.93% from CNY 7,844,239.23 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 45,936,845.59, up 1,191.12% from CNY 3,557,912.07 in the previous year[4] - Basic earnings per share increased to CNY 0.1649, up 519.92% from CNY 0.0266 in the previous year[4] - The company reported a net profit for Q1 2022 reached CNY 50,083,816.82, a significant increase of 438.73% compared to CNY 9,296,672.16 in Q1 2021[10] - Operating profit surged to CNY 57,757,451.57, reflecting a 454.92% increase from CNY 10,408,203.99 in the previous year, driven by higher sales volume and price increases[10] - Total profit amounting to CNY 57,545,947.50, up 429.66% from CNY 10,864,598.24[10] - The total comprehensive income for the first quarter was CNY 49,907,047.08, up from CNY 9,523,931.09 year-over-year[22] Cash Flow and Assets - The net cash flow from operating activities was CNY 26,157,813.52, a turnaround from a negative CNY 38,850,363.39 in the same period last year, marking a 167.33% improvement[4] - The cash and cash equivalents increased by 93.77% to CNY 181,185,946.20, primarily due to a reduction in financial management scale[9] - The total assets at the end of the reporting period were CNY 2,291,739,822.97, a slight increase of 0.25% from CNY 2,285,925,658.35 at the end of the previous year[4] - The total liabilities decreased from CNY 328,946,760.67 at the beginning of the year to CNY 283,302,217.62 by the end of the first quarter[20] - The accounts receivable rose to CNY 272,806,848.64 from CNY 229,877,761.81 at the beginning of the year[19] - The inventory level remained stable at CNY 145,751,581.05 compared to CNY 145,776,657.54 at the beginning of the year[19] Operating Costs and Expenses - The total operating costs for the first quarter of 2022 amounted to CNY 357,245,810.45, compared to CNY 307,109,062.73 in the previous period[21] - The company incurred a total operating expense of CNY 458,828,129.12, compared to CNY 320,550,716.32 in the same period last year[23] - Financial expenses rose dramatically by 383.17% to CNY 1,048,496.55, attributed to fluctuations in the RMB to USD exchange rate[10] - The company reported a decrease in research and development expenses to CNY 9,935,149.46 from CNY 12,750,543.55 in the previous period[21] Growth and Expansion Plans - The company plans to expand its production capacity for taurine food additives by 40,000 tons annually, with an investment of CNY 250 million from its own funds[14] - The company reported a significant increase in sales volume and unit price as the main reason for the revenue growth[9] Legal and Compliance - The company is actively addressing a patent infringement lawsuit filed in the U.S., indicating a commitment to protecting its intellectual property rights[14] Other Income - The company experienced a 34.46% increase in other income, totaling CNY 1,174,597.07, primarily due to government subsidies received by its subsidiaries[10] - The company recognized government subsidies amounting to CNY 1,174,597.07 related to asset-related government grants during the reporting period[7] Audit Status - The company has not undergone an audit for the first quarter report[25]